Literature DB >> 18512788

Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice.

Wei Yao1, Zhiqiang Cheng, Cheryl Busse, Aaron Pham, Mary C Nakamura, Nancy E Lane.   

Abstract

OBJECTIVE: Glucocorticoid (GC) excess induces alterations in bone metabolism that weaken bone structure and increase fracture risk. The aim of this study was to identify genes associated with bone metabolism in GC-treated mice, by performing a microarray analysis.
METHODS: Long bones from mice exposed to GC excess were collected after 0, 7, 28, and 56 days of treatment, to measure bone microarchitecture and extract RNA for microarray analyses.
RESULTS: Bone loss in this animal model was confirmed by changes in bone turnover markers as well as bone architecture, as measured by microfocal computed tomography. GC excess induced an early up-regulation of genes involved in osteoclast activation, function, and adipogenesis, which peaked on day 7. The expression of genes associated with osteoclast cytoskeletal reorganization and genes associated with matrix degradation peaked on day 28. On day 28 and day 56, the expression of genes associated with osteoblast activation and maturation was decreased from baseline, while the expression of Wnt antagonists was increased. In addition, the expression of genes expressed in osteocytes associated with bone mineralization was significantly higher at the later time points, day 28 and day 56. Reverse transcription-polymerase chain reaction confirmed the results of microarray analysis in selected genes.
CONCLUSION: GC excess is associated with early activation of genes associated with osteoclastogenesis and adipogenesis and a later suppression of genes associated with osteogenesis and mineralization. Novel interventions with agents that modulate either Wnt signaling or mineralization may be effective in GC-induced osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18512788      PMCID: PMC3892702          DOI: 10.1002/art.23454

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  50 in total

1.  Glucocorticoids induce the differentiation of a mesenchymal progenitor cell line, ROB-C26 into adipocytes and osteoblasts, but fail to induce terminal osteoblast differentiation.

Authors:  Shinsuke Ito; Naoto Suzuki; Shigeyuki Kato; Tomihisa Takahashi; Minoru Takagi
Journal:  Bone       Date:  2006-09-01       Impact factor: 4.398

Review 2.  DMP1 is essential for osteocyte formation and function.

Authors:  H F Rios; L Ye; V Dusevich; D Eick; L F Bonewald; J Q Feng
Journal:  J Musculoskelet Neuronal Interact       Date:  2005 Oct-Dec       Impact factor: 2.041

3.  Osteoclasts and integrins.

Authors:  Steven L Teitelbaum
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

4.  Glucocorticoids suppress bone formation via the osteoclast.

Authors:  Hyun-Ju Kim; Haibo Zhao; Hideki Kitaura; Sandip Bhattacharyya; Judson A Brewer; Louis J Muglia; F Patrick Ross; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

5.  Modulation of early human preadipocyte differentiation by glucocorticoids.

Authors:  Julianna J Tomlinson; Adèle Boudreau; Dongmei Wu; Ella Atlas; Robert J G Haché
Journal:  Endocrinology       Date:  2006-07-27       Impact factor: 4.736

6.  Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia.

Authors:  Ji Li; Ildiko Sarosi; Russell C Cattley; James Pretorius; Frank Asuncion; Mario Grisanti; Sean Morony; Stephen Adamu; Zhaopo Geng; Wanrong Qiu; Paul Kostenuik; David L Lacey; W Scott Simonet; Brad Bolon; Xueming Qian; Victoria Shalhoub; Michael S Ominsky; Hua Zhu Ke; Xiaodong Li; William G Richards
Journal:  Bone       Date:  2006-05-26       Impact factor: 4.398

7.  Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density.

Authors:  D Jia; C A O'Brien; S A Stewart; S C Manolagas; R S Weinstein
Journal:  Endocrinology       Date:  2006-08-24       Impact factor: 4.736

8.  Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism.

Authors:  Jian Q Feng; Leanne M Ward; Shiguang Liu; Yongbo Lu; Yixia Xie; Baozhi Yuan; Xijie Yu; Frank Rauch; Siobhan I Davis; Shubin Zhang; Hector Rios; Marc K Drezner; L Darryl Quarles; Lynda F Bonewald; Kenneth E White
Journal:  Nat Genet       Date:  2006-10-08       Impact factor: 38.330

Review 9.  Glucocorticoid-induced osteoporosis: an update.

Authors:  Gherardo Mazziotti; Alberto Angeli; John P Bilezikian; Ernesto Canalis; Andrea Giustina
Journal:  Trends Endocrinol Metab       Date:  2006 May-Jun       Impact factor: 12.015

10.  Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice.

Authors:  Nancy E Lane; Wei Yao; Mehdi Balooch; Ravi K Nalla; Guive Balooch; Stefan Habelitz; John H Kinney; Lynda F Bonewald
Journal:  J Bone Miner Res       Date:  2005-11-14       Impact factor: 6.741

View more
  87 in total

1.  Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?

Authors:  Steven L Teitelbaum; Margaret P Seton; Kenneth G Saag
Journal:  Arthritis Rheum       Date:  2011-02

Review 2.  Anti-inflammatory glucocorticoid drugs: reflections after 60 years.

Authors:  Michael W Whitehouse
Journal:  Inflammopharmacology       Date:  2010-10-31       Impact factor: 4.473

Review 3.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 4.  Glucocorticoid-induced osteoporosis.

Authors:  Stuart L Silverman; Nancy E Lane
Journal:  Curr Osteoporos Rep       Date:  2009-03       Impact factor: 5.096

5.  Ultrastructural characteristics of glucocorticoid-induced osteoporosis.

Authors:  B Bouvard; M Audran; E Legrand; D Chappard
Journal:  Osteoporos Int       Date:  2009-06       Impact factor: 4.507

Review 6.  Review of new guidelines for the management of glucocorticoid induced osteoporosis.

Authors:  Swamy R Venuturupalli; Wendy Sacks
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

7.  Adipogenesis and osteoblastogenesis: trans-differentiation in the pathophysiology of bone disorders.

Authors:  Ch Savopoulos; Ch Dokos; G Kaiafa; A Hatzitolios
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

Review 8.  WNT Signaling in osteoarthritis and osteoporosis: what is the biological significance for the clinician?

Authors:  Liesbet Lodewyckx; Rik J U Lories
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

9.  Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength.

Authors:  W Yao; W Dai; L Jiang; E Y-A Lay; Z Zhong; R O Ritchie; X Li; H Ke; N E Lane
Journal:  Osteoporos Int       Date:  2015-09-18       Impact factor: 4.507

10.  Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment.

Authors:  A H van Lierop; A W van der Eerden; N A T Hamdy; A R Hermus; M den Heijer; S E Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  2012-07-27       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.